Possis Medical, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Files registration with the Securities and Exchange Commission for 1,552,500 shares of common stock to be sold at 5-3/4 per share. Of the proceeds, 50% will fund R&D of additional uses of the company's three key products, the AngioJet thrombectomy system, the Perma-Flow graft, and the Perma-Seal graft. The products are all in human clinical trials in the U.S. and in "early stage sales" in Europe and Japan. An additional 25% of the proceeds will fund the clinical trials for the key products, and approximately $500,000 will be used for repayment of a loan. The offering includes 202,500 shares to cover over-allotments for underwriter John G. Kinnard and Company, Inc. Possis plans to issue warrants to the underwriter to purchase 120,000 additional shares. After the offering, 9.7 mil. shares of common stock will be outstanding
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.